All In Biotech

Free tool

FAERS Monitor: Zymfentra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761358 or its brand name (Zymfentra, Infliximab-Dyyb). Reports on generic versions are filed under their own applications.

Reports

3,446

Serious

2,649

77% of reports

Hospitalization

818

Death reported

93

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • inappropriate schedule of product administration991
  • off label use908
  • intentional dose omission840
  • product dose omission issue448
  • overdose320
  • suspected off label use311
  • weight decreased306
  • weight increased306
  • therapy interrupted294
  • arthralgia288
  • fatigue286
  • condition aggravated272
  • diarrhoea272
  • harvey-bradshaw index increased268
  • crohn^s disease259

Reports by year received

View as table
YearReports
20172
201812
20197
20209
202125
202259
2023153
2024382
2025882
20261,915

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
harvey-bradshaw index increasedSignal26854571.437474.01,466,806
suspected off label useSignal311451.2404.1129,690
intentional dose omissionSignal840185.3174.5149,430
inappropriate schedule of product administrationSignal99133.732.031,550
therapy interruptedSignal29425.222.66,806
product dose omission issueSignal4489.38.53,357
overdoseSignal3209.18.22,309
weight increasedSignal3068.47.51,991
weight decreasedSignal3066.76.01,495
off label useSignal9086.36.04,246
condition aggravatedSignal2725.54.91,001
arthralgiaSignal2884.23.8721
diarrhoeaSignal2722.62.3268
fatigueSignal2862.22.0203
crohn^s disease2590.00.01,576,079

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.